首页> 中文期刊> 《临床和实验医学杂志》 >奥扎格雷钠在治疗后循环缺血引起的发作性头晕中的应用价值研究

奥扎格雷钠在治疗后循环缺血引起的发作性头晕中的应用价值研究

         

摘要

目的 探讨奥扎格雷钠注射液在治疗后循环缺血引起的发作性头晕中的应用价值.方法 将收治的118例后循环缺血引起的头晕患者随机分为观察组和对照组各59例,对照组采用静脉滴注血塞通、口服阿司匹林等常规治疗,观察组在常规治疗的基础上联合使用奥扎格雷钠注射液治疗,比较两组患者起效时间、住院时间、治疗总有效率、不良反应发生率和治疗费用.结果 观察组患者治疗总有效率为83.05%,对照组为62.71%,两组总有效率比较差异具有统计学意义(χ2=12.710,P=0.000).观察组起效时间为(2.79±1.43)d,住院治疗时间为(12.25±4.50)d,明显低于对照组,两组间比较差异具有统计学意义(μ=6.674,12.350;P=0.000).结论 在常规治疗的基础上综合应用奥扎格雷钠治疗后循环缺血引起的发作性头晕可有效提高疗效,值得临床推广.%Objective To explore the efficacy of ozagrel sodium injection in treatment of paroxysmal dizziness caused by ischemic posterior loop of circulation. Methods One hundred and eighteen patients with paroxysmal dizziness caused by ischemic posterior loop of circulation in this hospital during were randomly divided into trial group and control group, each with 59 cases. Patients in control group were treated with routine therapy including intravenous infusion of Xuesaitong and oral administration of aspirin tablets, and patients in trial group were additionally given with injection of ozagrel sodium on the basis of routine treatment. The time for starting effectiveness of drug, duration of hospitalization, total rate of effectiveness, rate of adverse reactions and cost for treatment were compared between these two groups. Results The total effective rates in patients of trial group and control group were 83. 05% and 62. 71 % respectively, and the difference between these two groups was statistically significant(χ 2= 12.710, P = 0. 000 ). The time for starting effectiveness of drug in patients of trial group was ( 2. 79 ± 1.43 ) d, and their duration of hospitalization was ( 12. 25 ±4. 50 ) d, and they were obviously lower than those of control group, and the differences between these two groups was statistically significant ( u = 6. 674, 12. 350: P = 0. 000 ). Conclusion The comprehensive application of ozagrel sodium injection in treatment of paroxysmal dizziness caused by ischemic posterior loop of circulation can raise the curative effect, and it is worthy to be recommended for clinical application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号